Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CET

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
01/19 VANDA PHARMACEUTICALS : Reports Preliminary Fourth Quarter and Full Year 2016 Re..
01/19 VANDA PHARMACEUTICALS : to Announce Fourth Quarter and Full Year 2016 Financial ..
01/19 VANDA PHARMACEUTICALS : Patent Issued for Treatment of Circadian Rhythm Disorder..
01/10 VANDA PHARMACEUTICALS : Research Reports Coverage on Biotech Stocks -- Cara Ther..
01/09 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Results of Operations an..
01/09 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Regu..
01/09 VANDA PHARMACEUTICALS : Reports Preliminary Fourth Quarter and Full Year 2016 Re..
2016 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Other Events
2016 VANDA PHARMACEUTICALS INC. : Other Events (form 8-K)
2016 VANDA PHARMACEUTICALS : Settles Fanapt® Patent Litigation with Apotex
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/09 Vanda Pharmaceuticals reports preliminary Q4 and FY2016 results and 2017 guid..
2016 VANDA : Valued Like A Plain Pharma Company, But Isn't One
2016 Tracking John Paulson's Paulson & Company Portfolio - Q3 2016 Update
2016 Healthcare ratings roundup - new coverage
2016 BIOTECH FORUM DAILY DIGEST : DOJ Piles On Biopharma, Investment Case For Gilead ..
Advertisement
Financials ($)
Sales 2016 146 M
EBIT 2016 -21,8 M
Net income 2016 -20,9 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 3,92x
Capi. / Sales 2017 3,36x
Capitalization 574 M
More Financials
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,5 $
Spread / Average Target 72%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Vincent J. Milano Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..-18.18%574
AMGEN, INC.4.45%113 612
GILEAD SCIENCES, INC.-1.28%93 131
CELGENE CORPORATION-2.97%87 063
REGENERON PHARMACEUTIC..-3.47%37 374
ACTELION LTD1.18%24 865
More Results